Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model. 2009

Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China. cdmake@sohu.com

OBJECTIVE To investigate the effect of brimonidine on the retinal ganglion cell survival in an optic nerve crush model. METHODS Experimental animal study. METHODS Twenty-four Sprague-Dawley rats were divided into a study group of eight animals receiving intraperitoneal injections of brimonidine (1 mg/kg) and into a control group of 12 animals receiving intraperitoneal saline injections. All injections were performed one hour before the optic nerve crash and daily afterwards. For each animal, the right optic nerve was crushed for 60 seconds by a microclip with 40-g power. At 23 days after the optic nerve crush, the retinal ganglion cells were retrogradely labeled by injecting 3% fluorogold into both sides of the superior colliculus of the brain. At four weeks after the optic nerve crush, the animals were sacrificed. Photographs taken from retinal flat mounts were assessed for number and density of the retinal ganglion cells. RESULTS The retinal ganglion cell density of the right eyes with an optic nerve lesion was statistically significantly (P = .02) higher in the brimonidine study group (1281 +/- 189 cells/mm(2)) than in the control group (1060 +/- 148 cells/mm(2)). Correspondingly, the survival rate (ratio of retinal ganglion cell density in the right eye divided by cell density in the left eye) was statistically significantly (P = .027) higher in the study group than in the control group (61.0% +/- 6.0% vs 53.5+/-8.0%). CONCLUSIONS Intraperitoneal injections of brimonidine given prophylactically prior to and posttreatment daily after an experimental and standardized optic nerve crush in rats were associated with a higher survival rate of retinal ganglion cells.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D009409 Nerve Crush Treatment of muscles and nerves under pressure as a result of crush injuries. Crush, Nerve
D011810 Quinoxalines Quinoxaline
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000068438 Brimonidine Tartrate A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate,5-bromo-6-(imidazolidinylideneamino)quinoxaline,5-bromo-6-(imidazolin-2-ylamino)quinoxaline,AGN 190342,AGN-190342,Alphagan,Alphagan P,Brimonidine,Brimonidine Purite,Brimonidine Tartrate (1:1),Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer,Brimonidine Tartrate, (R-(R*,R*))-Isomer,Bromoxidine,Mirvaso,Ratio-Brimonidine,Sanrosa,UK 14,304,UK 14,304-18,UK 14304,UK 14308,UK-14,304-18,UK-14,308,UK-14304,AGN190342,Ratio Brimonidine,UK 14,304 18,UK 14,30418,UK 14,308,UK14,30418,UK14,308,UK14304
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012165 Retinal Ganglion Cells Neurons of the innermost layer of the retina, the internal plexiform layer. They are of variable sizes and shapes, and their axons project via the OPTIC NERVE to the brain. A small subset of these cells act as photoreceptors with projections to the SUPRACHIASMATIC NUCLEUS, the center for regulating CIRCADIAN RHYTHM. Cell, Retinal Ganglion,Cells, Retinal Ganglion,Ganglion Cell, Retinal,Ganglion Cells, Retinal,Retinal Ganglion Cell

Related Publications

Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
May 2017, Cellular and molecular biology (Noisy-le-Grand, France),
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
January 2016, Molecular vision,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
April 2011, Journal of visualized experiments : JoVE,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
January 2017, PloS one,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
December 2013, Investigative ophthalmology & visual science,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
August 2015, Investigative ophthalmology & visual science,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
March 2020, Bio-protocol,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
November 2012, Neuroscience,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
December 2023, Macromolecular rapid communications,
Ke Ma, and Liang Xu, and Haijuan Zhang, and Shixian Zhang, and Mingliang Pu, and Jost B Jonas
February 2015, Cell death & disease,
Copied contents to your clipboard!